DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis

DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis

IntroductionTriple-negative breast cancer (TNBC) is characterized by its aggressive nature and absence of specific therapeutic targets, necessitating the reliance on chemotherapy as the primary treatment modality. However, the drug resistance poses a significant challenge in the management of TNBC....

Full description

Bibliographic Details
Main Authors: Shiyu Cao, Xinyi Long, Lin Xiao, Peichuan Zhang, Mengjia Shen, Fei Chen, Chunjuan Bao, Xiaorong Zhong, Ting Luo, Feng Ye
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
TNBC
DDX58
chemotherapy resistance
Type I IFN
apoptosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1356778/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1356778/full

Similar Items